Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study

2017 ◽  
Vol 39 (1) ◽  
pp. 52-58 ◽  
Author(s):  
Randi Sokol ◽  
Chiara Albanese ◽  
Deviney Chaponis ◽  
Jessica Early ◽  
George Maxted ◽  
...  
2021 ◽  
pp. 106765
Author(s):  
Valerie S. Harder ◽  
Andrea C. Villanti ◽  
Sarah H. Heil ◽  
M. Lindsey Smith ◽  
Diann E. Gaalema ◽  
...  

2021 ◽  
pp. 1-8
Author(s):  
Caitlin E. Martin ◽  
Tawany Almeida ◽  
Bhushan Thakkar ◽  
Tiffany Kimbrough

2019 ◽  
Vol 134 (5) ◽  
pp. 456-460 ◽  
Author(s):  
Judith Steinberg ◽  
Alejandro Azofeifa ◽  
George Sigounas

Author(s):  
Lauren Caton ◽  
Hannah Cheng ◽  
Hélène Chokron Garneau ◽  
Tammy Fisher ◽  
Briana Harris-Mills ◽  
...  

Abstract Background With the onset of the COVID-19 crisis, many federal agencies relaxed policies regulating opioid use disorder treatment. The impact of these changes has been minimally documented. The abrupt nature of these shifts provides a naturalistic opportunity to examine adaptations for opioid use disorder treatment in primary care. Objective To examine change in medical and behavioral health appointment frequency, visit type, and management of patients with opioid use disorder in response to COVID-19. Design A 14-item survey queried primary care practices that were enrolled in a medications for opioid use disorder statewide expansion project. Survey content focused on changes in service delivery because of COVID-19. The survey was open for 18 days. Participants We surveyed 338 clinicians from 57 primary care clinics located in California, including federally qualified health centers and look-alikes. A representative from all 57 clinics (100%) and 118 staff (34.8% of all staff clinicians) participated in the survey. Main Measures The survey consisted of seven dimensions of practice: medical visits, behavioral health visits, medication management, urine drug screenings, workflow, perceived patient demand, and staff experience. Key Results A total of 52 of 57 (91.2%) primary care clinics reported practice adaptations in response to COVID-19 regulatory changes. Many clinics indicated that both medical (40.4%) and behavioral health visits (53.8%) were now exclusively virtual. Two-thirds (65.4%) of clinics reported increased duration of buprenorphine prescriptions and reduced urine drug screenings (67.3%). The majority (56.1%) of clinics experienced an increase in patient demand for behavioral health services. Over half (56.2%) of clinics described having an easier or unchanged experience retaining patients in care. Conclusions Many adaptations in the primary care approach to patients with opioid use disorder may be temporary reactions to COVID-19. Further evaluation of the impact of these adaptations on patient outcomes is needed to determine whether changes should be maintained post-COVID-19.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Alex K. Gertner ◽  
Jason S. Rotter ◽  
Margaret E. Holly ◽  
Christopher M. Shea ◽  
Sherri L. Green ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document